U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Condoms, Diaphragms, Sponge, Vaginal Ring, Subdermal Implants, IUD, Patch, Injectable), And Segment Forecasts, 2020 - 2027

Published: Feb, 2018 | Pages: 80 | Publisher: Grand View Research
Industry: Medical Devices | Report Format: Electronic (PDF)

The U.S. contraceptive market size is expected to reach USD 9.6 billion by 2027, exhibiting a 4.2% CAGR over the forecast period, based on a new report published by Grand View Research, Inc. Improving awareness regarding Long-Acting Reversible Contraceptives (LARCs) and effectiveness, availability, and convenience of using these products are the factors expected to drive the growth. The Guttmacher Institute reports that in U.S., 60% of women of reproductive age use contraception. Use of hormonal contraceptives other than the birth control pill has significantly increased among married women.

Key market players are actively investing in the clinical pipeline, resulting in high competition and an increase in the quality of contraceptives. In January 2019, Mithra Pharmaceuticals announced the success of Estelle’s phase 3 study conducted in U.S. and Canada, meeting the primary efficacy endpoint. The efficacy was reported to be similar to a recently FDA-approved Annovera and Lo-Loestrin. In November 2019, Agile Therapeutics, Inc. announced that the U.S. FDA had extended the review date of Twirla’s New Drug Application (NDA), from November 16, 2019 to February 16, 2020.

Further key findings from the study suggest:

• Prevalence of teenage pregnancies is highest in U.S. among developed nations. Government initiatives such as improving sex education and increasing access to contraceptives is expected to drive adoption of various birth control method among young population

• In 2019, the pills segment held the largest market share owing to the convenience of use and easy availability. The pills market is highly competitive due to the presence of generic products

• Intrauterine Devices (IUDs) held one of the largest market shares in 2019, with increasing demand for hormonal IUDs

• Rapid growth of subdermal implants in the U.S. contraceptive market is anticipated in the coming years. The market for subdermal implants is highly consolidated with presence of very few players

• Nonhormonal birth control methods such as condoms, sponge, and diaphragms are popular among women in the age group of 25 to 40 years

• Some of the key industry contributors are Merck & Co. Inc.; Bayer AG; Allergan, Afaxys, Inc; Mayer Laboratories, Inc.; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; TherapeuticsMD Inc.; Reckitt Benckiser Plc.; Pfizer, Inc.; Cooper Surgical; Church & Dwight Co., Inc.; Mithra Pharmaceuticals

 Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Objectives
                       1.1.1. Objective - 1
                       1.1.2 Objective - 2
Chapter 2 Executive Summary
                   2.1 Market Outlook
                   2.2 Segment Outlook
                       2.2.1 Product
                   2.3 Competitive Insights
Chapter 3 Market Variables, Trends & Scope
                   3.1 Market Lineage outlook
                       3.1.1 Parent Market Outlook
                   3.2 Market Segmentation
                   3.3 Market Dynamics
                       3.3.1 Market Driver Analysis
                           3.3.1.1 Technological advancements
                           3.3.1.2 Initiatives by social organizations to improve the access of condom to avoid Sexually Transmitted Diseases (STDs)
                           3.3.1.3 Increasing Prevalance of unwanted pregnancies
                       3.3.2 Market Restraint Analysis
                           3.3.2.1 Increasing geriartic population and rising prevalence of infertility
                           3.3.2.2 Adverse effects associated with use of contraceptive drugs and devices
                   3.4 Business Environment Analysis Tools
                       3.4.1 Porter’s Five Forces Analysis
                       3.4.2 PESTEL Analysis
                   3.5 Penetration & Growth Prospect Mapping
                       3.5.1 Analysis
                   3.6 Pipeline Analysis
                   3.7 Regulatory Scenario and Reimbursement Framework, 2019
                   3.8 Major Deals & Strategic Alliances Analysis
                       3.8.1 Mergers Acquisition & Joint Ventures
                       3.8.2 Lisencing Partnerships & Technology Collaborations
Chapter 4 U.S. Contraceptive Market: Product Analysis
                   4.1 U.S. Contraceptive Product Market Share Analysis, 2019 & 2027
                   4.2 U.S. Contraceptive Product Market: Segment Dashboard
                   4.3 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the Product Segment
                       4.3.1 PILLS
                           4.3.1.1 Pills market, 2016 - 2027 (USD Million)
                       4.3.2 Condoms
                           4.3.2.1 Condoms market, 2016 - 2027 (USD Million)
                               4.3.2.1.1 Male condom market, 2016 - 2027 (USD Million)
                               4.3.2.1.2 Female condom market, 2016 - 2027 (USD Million)
                       4.3.3 Diaphragms
                           4.3.3.1 Diaphragms Market, 2016 - 2027 (USD Million)
                       4.3.4 Sponge
                           4.3.4.1 Sponge market, 2016 - 2027 (USD Million)
                       4.3.5 Vaginal Ring
                           4.3.5.1 Vaginal ring market, 2016 - 2027 (USD Million)
                       4.3.6 Subdermal Implant
                           4.3.6.1 Subdermal implant market, 2016 - 2027 (USD Million)
                       4.3.7 IUD
                           4.3.7.1 IUD market, 2016 - 2027 (USD Million)
                               4.3.7.1.1 Hormonal IUD market, 2016 - 2027 (USD Million)
                               4.3.7.1.2 Nonhormonal IUD market, 2016 - 2027 (USD Million)
                       4.3.8 Patch
                           4.3.8.1 PATCH market, 2016 - 2027 (USD Million)
                       4.3.9 Injectable Contraceptives
                           4.3.9.1 Injectable market, 2016 - 2027 (USD Million)
Chapter 5 Competitive Analysis
                   5.1 Recent developments & impact analysis, by key market participants
                   5.2 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players)
                   5.3 Public & Private Companies
                       5.3.1 Company Market Position Analysis (Market Presence, Geographic Presence, Product Portfolio, Overall Revenue, And Strategic Initiatives)
                   5.4 Company Profiles
                       5.4.1 MERCK & CO., INC
                           5.4.1.1 Company overview
                           5.4.1.2 Financial performance
                           5.4.1.3 Product benchmarking
                           5.4.1.4 Strategic initiatives
                           5.4.1.5 SWOT analysis
                       5.4.2 BAYER AG
                           5.4.2.1 Company overview
                           5.4.2.2 Financial performance
                           5.4.2.3 Product benchmarking
                           5.4.2.4 Strategic initiatives
                           5.4.2.5 SWOT analysis
                       5.4.3 ALLERGAN
                           5.4.3.1 Company overview
                           5.4.3.2 Financial performance
                           5.4.3.3 Product benchmarking
                           5.4.3.4 Strategic initiative
                           5.4.3.5 SWOT analysis
                       5.4.4 PFIZER, INC.
                           5.4.4.1 Company overview
                           5.4.4.2 Financial Performance
                           5.4.4.3 Product benchmarking
                           5.4.4.4 Strategic initiatives
                           5.4.4.5 SWOT analysis
                       5.4.5 AFAXYS, INC.
                           5.4.5.1 Company overview
                           5.4.5.2 Product benchmarking
                           5.4.5.3 Strategic initiatives
                           5.4.5.4 SWOT analysis
                       5.4.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
                           5.4.6.1 Company overview
                           5.4.6.2 Financial performance
                           5.4.6.3 Strategic initiatives
                           5.4.6.4 SWOT analysis
                       5.4.7 AGILE THERAPEUTICS
                           5.4.7.1 Company overview
                           5.4.7.2 Financial performance
                           5.4.7.3 Product benchmarking
                           5.4.7.4 Strategic initiatives
                           5.4.7.5 SWOT analysis
                       5.4.8 APOTHECUS PHARMACEUTICAL CORP.
                           5.4.8.1 Company overview
                           5.4.8.2 Product benchmarking
                       5.4.9 MAYER LABORATORIES, INC.
                           5.4.9.1 Company overview
                           5.4.9.2 Product benchmarking
                       5.4.10 THE COOPER COMPANIES, INC.
                           5.4.10.1 Company overview
                           5.4.10.2 Financial performance
                           5.4.10.3 Product benchmarking
                           5.4.10.4 Strategic initiative
                           5.4.10.5 SWOT analysis
                       5.4.11 BLAIREX LABORATORIES, INC.
                           5.4.11.1 Company overview
                           5.4.11.2 Product benchmarking
                       5.4.12 THERAPEUTICSMD, INC.
                           5.4.12.1 Company overview
                           5.4.12.2 Financial performance
                           5.4.12.3 Product benchmarking
                           5.4.12.4 Strategic initiative
                           5.4.12.5 SWOT analysis
                       5.4.13 MITHRA PHARMACEUTICALS
                           5.4.13.1 Company overview
                           5.4.13.2 Financial performance
                           5.4.13.3 Product benchmarking
                           5.4.13.4 Strategic initiatives
                           5.4.13.5 SWOT analysis
                       5.4.14 Church & Dwight Co., Inc.
                           5.4.14.1 Company overview
                           5.4.14.2 Financial performance
                           5.4.14.3 Product benchmarking
                           5.4.14.4 Strategic initiatives
                           5.4.14.5 SWOT analysis
                       5.4.15 Reckitt Benckiser Plc
                           5.4.15.1 Company overview
                           5.4.15.2 Financial performance
                           5.4.15.3 Product benchmarking
                           5.4.15.4 Strategic initiatives
                           5.4.15.5 SWOT analysis
Chapter 6 Recommendations
Chapter 7 Research Methodology & Scope
                   7.1 Market Definition
                       7.1.1 Product
                   7.2 Research Methodology
                   7.3 Information Procurement
                       7.3.1 Purchased Database
                       7.3.2 Gvr’s Internal Database
                       7.3.3 Secondary Sources
                       7.3.4 Primary Research
                   7.4 Information or Data Analysis
                       7.4.1 Data Analysis Models
                   7.5 Market Formulation & Validation
                   7.6 Model Details
                       7.6.1 Commodity Flow Analysis
                       7.6.2 Variable Analysis
                   7.7 List of Secondary Sources
                   7.8 List of Primary Sources
                   7.9 List of Abbreviations
Chapter 8 Report FAQs
                   8.1 How do I trust your report quality/data accuracy?
                   8.2 My research requirement is very specific; can I customize this report?
                   8.3 I have a pre-defined budget. Can I buy chapters/sections of this report?
                   8.4 How do you arrive at these market numbers?
                   8.5 Who are your clients?
                   8.6 How will I receive this report?
Chapter 9 Appendix
Chapter 10 Compass - Cloud Based Report Delivery Platform
Chapter 11 Related Reports

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 U.S. Contraceptive Market, By Product, 2016 - 2027 (USD million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market outlook 2019 (USD Million)
Fig. 9 U.S. contraceptive market segmentation
Fig. 10 Market trends & outlook
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 PORTER'S five forces analysis
Fig. 14 PESTLE analysis
Fig. 15 Penetration & growth prospect mapping
Fig. 16 U.S. contraceptive product market share analysis, 2019 & 2027 (USD Million)
Fig. 17 U.S. contraceptive product market: Segment dashboard
Fig. 18 Pills market, 2016 - 2027 (USD Million)
Fig. 19 Condoma market, 2016 - 2027 (USD Million)
Fig. 20 Male Condoms market, 2016 - 2027 (USD Million)
Fig. 21 Female Condoms market, 2016 - 2027 (USD Million)
Fig. 22 Diaphargms market, 2016 - 2027 (USD Million)
Fig. 23 Sponge market, 2016 - 2027 (USD Million)
Fig. 24 Vaginal ring market, 2016 - 2027 (USD Million)
Fig. 25 Subdermal implants market, 2016 - 2027 (USD Million)
Fig. 26 IUD market, 2016 - 2027 (USD Million)
Fig. 27 Hormonal IUD market, 2016 - 2027 (USD Million)
Fig. 28 Nonhormonal IUD market, 2016 - 2027 (USD Million)
Fig. 29 Patch market, 2016 - 2027 (USD Million)
Fig. 30 Injectable market, 2016 - 2027 (USD Million)
Fig. 31 Impact analysis by key market participants
Fig. 32 Strategy framework / Competition categorization
Fig. 33 Company market position analysis (service portfolio, strategic initiatives, market presence)